Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | PTPRB | P23467 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16994587 | 0.88 | ALDH1A1 (0.33) | ALDH1A1CYP3A4MMP1MMP9MMP13 | |
| SCHEMBL18927312 | 0.84 | ALDH1A1 (0.32) | ALDH1A1CYP3A4MMP1MMP9MMP13 | |
| SCHEMBL18937756 | 0.84 | MMP1 (0.33) | ALDH1A1CYP3A4MMP1MMP9MMP13 | |
| SCHEMBL27893535 | 0.82 | CYP2C19 (0.33) | ALDH1A1CYP3A4 | |
| SCHEMBL12333972 | 0.81 | ALDH1A1 (0.32) | ALDH1A1CYP3A4MMP1MMP9MMP13 | |
| SCHEMBL30253452 | 0.81 | ALDH1A1 (0.30) | ALDH1A1CYP3A4 | |
| SCHEMBL31454014 | 0.80 | ALDH1A1 (0.32) | ALDH1A1CYP3A4 | |
| SCHEMBL1316720 | 0.79 | ALDH1A1 (0.37) | ALDH1A1CYP3A4MMP1MMP9MMP13 | |
| SCHEMBL20502638 | 0.77 | ALDH1A1 (0.36) | ALDH1A1CYP3A4MMP1MMP9MMP13 | |
| SCHEMBL22498238 | 0.77 | ALDH1A1 (0.36) | ALDH1A1CYP3A4MMP1MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716947-B1 | CYCLOPOLYMERIZED USING SUPERCRITICAL OR SUBCRITICAL CARBON DIOXIDE AS A SOLVENT WITH TRANSITION METAL CHLORIDE CATALYST | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-04-06 | — | — | US | claimed |
| US-20240190880-A1 | SMALL MOLECULE DEGRADERS OF ESTROGEN RECEPTOR WITH CEREBLON LIGANDS | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-06-13 | — | — | US | disclosed |
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-06-01 | — | — | US | disclosed |
| EP-4126855-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-02-08 | — | — | EP | disclosed |
| US-20220388978-A1 | CEREBLON E3 LIGASE INHIBITORS | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-12-08 | — | — | US | disclosed |
| US-20220380368-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-12-01 | — | — | US | disclosed |
| CN-115298176-A | Compounds and their use in the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2022187588-A1 | SMALL MOLECULE DEGRADERS OF ESTROGEN RECEPTOR WITH CEREBLON LIGANDS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-4031241-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | The Regents Of The University Of Michigan (US) | 2022-07-27 | — | — | EP | disclosed |
| EP-4021580-A1 | CEREBLON E3 LIGASE INHIBITORS | The Regents Of The University Of Michigan (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-113527360-A | Application of phosphine nitrogen ligand and complex thereof in catalyzing asymmetric reaction | 南方科技大学 | 2021-10-22 | — | — | CN | disclosed |
| WO-2021190727-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2021-09-30 | — | — | WO | disclosed |
| CN-106543232-B | Metal bridge location fused ring compound and its preparation method and application | 厦门大学 | 2019-01-11 | — | — | CN | disclosed |
| WO-2009044130-A1 | BIARYL DIPHOSPHINES | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2009-04-09 | — | — | WO | disclosed |
| CN-1951903-A | Process for preparing 2-cyclohexenone compounds | UNIV ZHEJIANG (CN) | 2007-04-25 | — | — | CN | disclosed |
| US-6716947-B1 | CYCLOPOLYMERIZED USING SUPERCRITICAL OR SUBCRITICAL CARBON DIOXIDE AS A SOLVENT WITH TRANSITION METAL CHLORIDE CATALYST | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-04-06 | — | — | US | disclosed |
| US-6716947-B1 | CYCLOPOLYMERIZED USING SUPERCRITICAL OR SUBCRITICAL CARBON DIOXIDE AS A SOLVENT WITH TRANSITION METAL CHLORIDE CATALYST | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-04-06 | — | — | US | disclosed |
| US-6716947-B1 | CYCLOPOLYMERIZED USING SUPERCRITICAL OR SUBCRITICAL CARBON DIOXIDE AS A SOLVENT WITH TRANSITION METAL CHLORIDE CATALYST | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | AR, GPER1, CRBN | ALDH1A1 291/4885CYP3A4 421/4885MMP1 1736/4885 |
| US-20220380368-A1 | SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS | AR, NR5A1, ESRRA | ALDH1A1 132/4885CYP3A4 597/4885MMP1 1105/4885 |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | LTB4R, C5, C3AR1 | ALDH1A1 842/4885CYP3A4 374/4885MMP1 1134/4885 |
| US-20240190880-A1 | SMALL MOLECULE DEGRADERS OF ESTROGEN RECEPTOR WITH CEREBLON LIGANDS | ESR1, CRBN, ESR2 | ALDH1A1 1261/4885CYP3A4 856/4885MMP1 3892/4885 |
| US-20220388978-A1 | CEREBLON E3 LIGASE INHIBITORS | CRBN, CUL3, UBE3A | ALDH1A1 3487/4885CYP3A4 4192/4885MMP1 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.